Impact of Omega 3 in Alcohol Use Disorder

Launched by UNIVERSITÉ CATHOLIQUE DE LOUVAIN · Jun 1, 2023

Keywords

ClinConnect Summary

**Clinical Trial Summary: Impact of Omega 3 in Alcohol Use Disorder**

This clinical trial is exploring whether omega-3 fatty acids, commonly found in fish oil, can improve mental health in people struggling with alcohol use disorder (AUD). Researchers want to find out if these omega-3s can help with issues like depression, anxiety, cravings for alcohol, and problems with thinking and socializing. They are also interested in understanding if the positive effects of omega-3s come from changes in gut bacteria or inflammation in the body.

To participate, individuals need to be between 18 and 70 years old, have a diagnosis of alcohol use disorder, and be currently undergoing a three-week alcohol withdrawal program. Participants will take either omega-3 supplements or a placebo (olive oil) for three months and will undergo a variety of assessments, including brain scans and psychological tests. They will also provide blood, stool, and saliva samples for research purposes. This study is currently recruiting participants, and it is important to note that certain health conditions and recent medications could prevent someone from joining. If you or someone you know is interested, please reach out to the study team for more information!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of alcohol use disorder (≥ 4 DSM-5 criteria)
• • Patient at the hospital for a 3 week alcohol withdrawal program
• • Gender : male and female
• • Age : between 18 and 70 years old
• • Language : french
• • Alcohol consumption less than 48 jours before admission
• Exclusion Criteria:
• • Presence of another addiction, except for smoking and cannabis use
• • Presence of a psychiatric comorbidity (axis 1 DSM-5)
• • Current or recent use (\< 2 months) of antibiotics, probiotics, fibre supplements
• • Current or recent (\< 2 months) use of omega-3 supplements
• • Current or recent (\< 2 months) use of oral anti-coagulants drugs
• • Current or recent (\< 2 months) double anti-platelet therapy
• • Coagulation disorders
• • Current or recent (\< 1 month) use of non-steroidal anti-inflammatory drugs and glucocorticoids
• • Morbid obesity : body mass index \> 35 kg.m-2
• • Bariatric surgery
• • Type I diabetes and type II diabetes not stabilised (i.e. glycated haemoglobin \> 7.2 and unstable drug treatments)
• • Chronic inflammatory diseases
• • Cancer (less than 5 years before admission)
• • Presence of cirrhosis (Fibroscan® = F4 and echodoppler performed as part of clinical routine on patient admission)
• • Known allergy to fish and seafood
• • Any other comorbidity that would be a contraindication to the study in the judgement of the principal investigator